We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-0.37%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.75B
AUM Growth
-$41.8M
Cap. Flow
+$154M
Cap. Flow %
2.69%
Top 10 Hldgs %
69.08%
Holding
53
New
7
Increased
13
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$253M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$146M
3
GLUE icon
Monte Rosa Therapeutics
GLUE
+$67.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$52.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$28.6M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$128M
2
TVTX icon
Travere Therapeutics
TVTX
+$31.2M
3
RLMD icon
Relmada Therapeutics
RLMD
+$20.5M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$17.9M
5
RLAY icon
Relay Therapeutics
RLAY
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PNT
51
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-1,000,000
Closed -$10.5M
JNCE
52
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-555,000
Closed -$5.7M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Avoro Capital Advisors held 53 positions worth $5.75B, down 0.72% from $5.79B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors's Q2 2021 filing shows 7 new, 13 increased, 8 reduced and 7 closed positions. Its largest new stake was Ascendis Pharma A/S: 1,900,000 shares worth $250M. The largest sale was Vertex Pharmaceuticals, an estimated $128M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier.

  • Avoro Capital Advisors's largest Q2 2021 buy was Ascendis Pharma A/S: 1,900,000 shares worth $250M.
  • Avoro Capital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $52.2M increase.
  • Avoro Capital Advisors's biggest Q2 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $128M.
  • Avoro Capital Advisors fully exited Travere Therapeutics in Q2 2021, selling an estimated $31.2M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $5.75B portfolio in Q2 2021.
  • Avoro Capital Advisors opened 7 new positions and closed 7 in Q2 2021.
  • Avoro Capital Advisors's portfolio value fell 0.72% quarter-over-quarter to $5.75B.

Based on Avoro Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.